Biomea Fusion
Yahoo Finance • 17 days ago
Biomea Fusion Announces KOL Presentation and Interview on Menin and Icovamenib at WCIRDC 2025
Key Opinion Leader, Dr. Ralph DeFronzo presents the “Future of Menin Inhibitors” and discusses icovamenib and its clinical results shared during WCIRDC 2025 in online interview SAN CARLOS, Calif., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Biome... Full story
Yahoo Finance • 21 days ago
Biomea Fusion Presents COVALENT-111 Study Results at the 23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)
SAN CARLOS, Calif., Dec. 05, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or “Biomea Fusion” or “the Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today announced that it presented COVALENT-111 study... Full story
Yahoo Finance • 25 days ago
Biomea Fusion Announces Oral Presentation of Icovamenib at the 23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)
SAN CARLOS, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or “Biomea Fusion” or “the Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today announced that it has been selected for an oral... Full story
Yahoo Finance • 25 days ago
Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
SAN CARLOS, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or the “Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity medicines company, today announced that on November 26, 2025, the compensation co... Full story
Yahoo Finance • last month
Biomea Fusion to Participate at Upcoming Investor Conferences
SAN CARLOS, Calif., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or “Biomea Fusion” or “the Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today announced that it will participate in the upcom... Full story
Yahoo Finance • 2 months ago
Biomea Fusion to Present Poster Presentations at ObesityWeek®2025
SAN CARLOS, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity medicines company, today announced that it will present poster presentations at ObesityWeek® 2025,... Full story
Yahoo Finance • 2 months ago
Biomea Fusion to Participate in Citi's SMID Biotech C-Suite Fireside Chat Series
SAN CARLOS, Calif., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today announced that it will participate in Citi’s SMID Biotech C-Suite Fireside Chat Ser... Full story
Yahoo Finance • 3 months ago
Biomea Fusion announces pricing of public offering of securities
* Biomea Fusion (NASDAQ:BMEA [https://seekingalpha.com/symbol/BMEA]) announced the pricing of its public offering for gross proceeds of $25 million. * The offer consists of 11.19M shares of its common stock and accompanying warrants to... Full story
Yahoo Finance • 3 months ago
Biomea Fusion Announces Pricing of Public Offering of Securities
SAN CARLOS, Calif., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today announced the pricing of its previously announced underwritten public offering cons... Full story
Yahoo Finance • 3 months ago
Biomea Fusion rises after results from type 2 diabetes drug
[Teenager With Type 1 Diabetes Takes at Home Test] kyotokushige Biomea Fusion (NASDAQ:BMEA [https://seekingalpha.com/symbol/BMEA]) shares rose after reporting positive results from its mid-stage study testing icovamenib in individuals wit... Full story
Yahoo Finance • 3 months ago
Biomea Fusion Announces Proposed Public Offering of Securities
SAN CARLOS, Calif., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, announced today that it has commenced an underwritten public offering of shares of its co... Full story
Yahoo Finance • 3 months ago
Biomea Fusion Announces Positive 52-Week Results from Phase II COVALENT-111 Study in Type 2 Diabetes Demonstrating Non-Chronic Treatment with Icovamenib Benefits Two Distinct Patient Populations
Icovamenib showed a sustained treatment benefit at Week 52 (9 months past the end of treatment) in the severe insulin-deficient diabetes patient population taking one or more antihyperglycemic medications at baseline, with a 1.8% placebo a... Full story
Yahoo Finance • 3 months ago
Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
SAN CARLOS, Calif., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or the “Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity medicines company, today announced that on September 24, 2025, the compensation c... Full story
Yahoo Finance • 4 months ago
American International Group (AIG) Shares Cross Below 200 DMA
In trading on Friday, shares of American International Group Inc (Symbol: AIG) crossed below their 200 day moving average of $57.73, changing hands as low as $57.67 per share. American International Group Inc shares are currently trading... Full story
Yahoo Finance • 4 months ago
Five Below upgraded, Bill downgraded: Wall Street's top analyst calls
The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top Upgrades: Telsey Advisory upgraded Five Below(FIVE... Full story
Yahoo Finance • 6 months ago
Biomea Fusion Presents New Preclinical and Clinical Data on Icovamenib at the 85th Scientific Sessions of the American Diabetes Association (ADA)
In a rodent model of type 2 diabetes (T2D), icovamenib in combination with low-dose semaglutide promoted enhanced glycemic control and body weight reduction with complete preservation of lean mass, outperforming the group given semaglutide... Full story
Yahoo Finance • 6 months ago
Biomea Fusion Reports Preclinical Data for BMF-650, a Next-Generation Oral GLP-1 Receptor Agonist Candidate, Demonstrating Robust Weight Loss and Appetite Suppression in Obese Non-Human Primates
Dose-dependent, marked reductions in food intake and significant weight loss observed in obese cynomolgus monkeys BMF-650 compared favorably to published data of a leading GLP-1 RA candidate IND filing on track for the second half of 2025;... Full story
Yahoo Finance • 6 months ago
Meta, Peloton and Hasbro rise premarket; AstraZeneca falls
Investing.com -- U.S. stock futures edged higher Wednesday, as traders digested the ongoing conflict in the Middle East as well as the conclusion of the latest Federal Reserve meeting. Here are some of the biggest premarket U.S. stock mov... Full story
Yahoo Finance • 6 months ago
Biggest stock movers Wednesday: UBS, BTDR, and more
[Mixed group of millennial aged friends discuss investing and cryptocurrency trading] Trevor Williams Stock futures edged higher early Wednesday as investors awaited the Federal Reserve’s interest rate decision due later in the day. Here... Full story
Yahoo Finance • 6 months ago
Biomea Fusion launches public offering of common stock and warrants
REDWOOD CITY, Calif. - Biomea Fusion, Inc. (NASDAQ:BMEA), a clinical-stage diabetes and obesity company with a market capitalization of $109 million, announced Tuesday it has commenced an underwritten public offering of common stock shares... Full story
